Nexstim Selects Clinipace Worldwide to Manage Clinical Trial
Clinipace Brings Strategic Level of Global Regulatory and Development Experience to Novel Therapy Trial
Nexstim, a Finland-based compant involved with image-guided transcranial magnetic stimulation, has selected Clinipace Worldwide to manage the US-based clinical trial for the Navigated Brain Therapy System.
Nexstim launched a novel NBT device in 2012 for the treatment of brain injury and disease using repetitive transcranial magnetic stimulation (rTMS). The company reports that initial results show promise in helping stroke patients regain lost motor control, and that the NBT System also enables personalized non-drug treatment for people suffering from major depressive disorder (clinical depression).
Though the NBT System meets the requirements of the European Medical Devices Directive (MDD) and has been CE marked, the NBT System and therapeutic use for stroke and depression are not cleared indications in the US.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
